Loading...
•
Mar 31, 2025
Kura Oncology Q1 2025 Earnings Report
Kura Oncology reported its financial results for the first quarter of 2025, highlighting key milestones in its clinical programs and financial position.
Key Takeaways
Kura Oncology reported a net loss of $57.4 million for the first quarter of 2025, compared to a net loss of $49.5 million for the same period in 2024. The company's collaboration revenue significantly increased to $14.1 million from no revenue in the prior year, driven by its partnership with Kyowa Kirin. Research and development expenses rose to $56.0 million, reflecting increased clinical activities. The company ended the quarter with $658.2 million in cash, cash equivalents, and short-term investments, with a pro forma cash of $703.2 million after accounting for a $45 million milestone payment.
NDA for ziftomenib submitted to FDA in Q1 2025 for relapsed or refractory AML with NPM1 mutation, triggering a $45 million milestone payment from Kyowa Kirin.
Positive topline results from KOMET-001 (ziftomenib in R/R NPM1-m AML) accepted for oral presentation at ASCO and EHA.
First patients dosed in KOMET-015 trial evaluating ziftomenib plus imatinib in advanced GIST after imatinib failure.
Pro forma cash, cash equivalents, and short-term investments of $703.2 million as of March 31, 2025, expected to fund operations into 2027 and support ziftomenib commercialization.
Revenue by Segment
Forward Guidance
Kura Oncology anticipates several key milestones in 2025, including further clinical data presentations, initiation of Phase 3 trials for ziftomenib, and advancement of its other pipeline programs, supported by its strong financial position.
Positive Outlook
- Present data from KOMET-001 Phase 1b/2 trial in R/R NPM1-m AML at ASCO and EHA in Q2 2025.
- Present preliminary clinical data from KOMET-007 Phase 1b expansion cohort (ziftomenib with intensive chemotherapy) at EHA in Q2 2025.
- Initiate two independent Phase 3 registration-enabling trials in 1L intensive (KOMET-017-IC) and non-intensive (KOMET-017-NIC) AML in H2 2025.
- Nominate a development candidate for next-generation menin inhibitor program in diabetes in mid-2025.
- Present data from FIT-001 Phase 1 trial evaluating KO-2806 and cabozantinib in patients with renal cell carcinoma in H2 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...